Telix AGM 2022
Telix's 2022 AGM was held on Wednesday, 18th May 2022 at The Events Centre in Melbourne, Australia.
Telix at ANZSNM Annual Scientific Meeting 2022
Telix is a title partner of the 52nd Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting (ASM) being held this week in Brisbane, Queensland, 13-15 May.
First Patient Dosed in Phase II Renal Cancer Theranostics Study
Telix announces that a first patient has been dosed in the ‘STARLITE 2’ Phase II study of the Company’s investigational renal cancer therapy at MSK in New York.
Telix Further Strengthens European Distribution Network for Illuccix
Telix announces agreements with Avanço and THP for the distribution of Telix’s prostate cancer investigational imaging product for the Portuguese and Austrian, Czech Republic and Slovak Republic markets.
Activities Report and Appendix 4C for March 2022 Quarter
Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 March 2022
First Patients Dosed with Illuccix® – Telix’s Approved Prostate Cancer Imaging Agent
Telix announces the first commercial doses of its prostate cancer imaging agent, Illuccix®
Notice of Annual General Meeting 2022
Telix provides notice of The Annual General Meeting of Shareholders on Wednesday 18 May 2022
ProstACT Update: TARGET Study Ethics Approval
Telix’s ProstACT TARGET Phase II clinical trial of prostate cancer antibody therapy candidate TLX591 has been granted Human Research Ethics Committee approval.
Telix Announces Licence Agreement with Lilly for Olaratumab
Telix announces a licence agreement for Lilly’s olaratumab antibody, for diagnosis and treatment of human cancers.
PSMA-PET Imaging to be Funded through Medicare in Australia from July
Telix welcomes the listing of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) (PSMA-PET) imaging for patients with prostate cancer on the Medicare Benefits Schedule (MBS) from 1 July 2022.